#4 ~ 2(0 "

PATENT

Attorney Docket No. DX0644KBK

CN 028008

5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Rene DE WAAL MALE

Serial No.:

10/083,720

Filed: February 28, 2002

For:

MAMMALIAN CYTOKINE;

RELATED REAGENTS

|| Examiner:

not assigned

Art Unit:

not assigned

COMPUTER READABLE SEQUENCE SUBMISSION

Palo Alto, California 94304

July 8

_, 2002

U.S. Patent and Trademark Office BOX SEQUENCE, P.O. Box 2327 Arlington, VA 22202

15 Sir:

COMPLIANCE WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

In order to comply with requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures, for the above-identified application, in accordance with 37 CFR § 1.821 - 1.825, Applicants hereby submit: (1) a write-protected diskette containing a computer-readable submission for the "Sequence Listing"; and (2) a "Sequence Listing" paper copy of the contents of the diskette.

REMARKS

generated by the Patent Office's PATENTIN program. The Diskette should comply with the requirements of 37 CFR §1.824 and is IBM PC compatible with a

PC-DOS/MS-DOS operating system. If the diskette has been damaged, please call Applicants and a replacement diskette will be provided. A hard paper copy printout of the diskette is attached thereto.

I hereby state the informational contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR 1.821(c) and (e), respectively, are believed to be the same. This submission introduces no new matter, since enclosed sequences are the same as sequences which were submitted in priority documents.

Applicants have invested significant labor and care in preparing the present submission. The enclosed items are a bona fide effort to bring the present application into full compliance with the rules for sequence submissions. Should this not be the case, Applicants respectfully request notification of specific deficiencies and an opportunity for remedy, as described in 37 CFR 1.135(c).

Applicants believe that no fees are required; however, if any fees are required by the present Response, the Commissioner is authorized to charge any fees or credit any overpayment to DNAX Research Institute Deposit Account No. 04-1239.

Respectfully submitted,

25

20

5

1.0

15

Dated: July 8

Bv:

Sheela Mohan-Peterson Attorney for Applicants

Reg. Nó. 41,201

30

enclosures and attachments:

one write-protected diskette (CRM)

paper copy of contents of diskette (11 pages)

35

.1 ^

Customer Number 028008 DNAX Research Institute 901 California Avenue Palo Alto, California 94304-1104

Tel: (650) 852-9196

page 2 of 2